U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C29H34O6
Molecular Weight 478.5767
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIBENOSIDE

SMILES

CCOC1O[C@H]([C@@H](COCC2=CC=CC=C2)OCC3=CC=CC=C3)[C@H](OCC4=CC=CC=C4)[C@H]1O

InChI

InChIKey=ULLNJSBQMBKOJH-VIVFLBMVSA-N
InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25-,26-,27-,28-,29?/m1/s1

HIDE SMILES / InChI
Molecular Formula C29H34O6
Molecular Weight 478.5767
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 4 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: DOI:10.1159/000135957 http://www.rad-ar.or.jp/siori/print.cgi?n=14678 http://www.ncbi.nlm.nih.gov/pubmed/578928

Tribenoside, a glucofuranoside derivative has been shown to have potent anti-allergic and anti-inflammatory properties. It has been reported to display a pluripotent antagonistic action against histamine, serotonin, bradykinin and other inflammatory substances. Tribenoside decrease capillary permeability, thus reducing edema. Tribenoside combat the pathological processes of capillaries and veins. It is used in adults and adolescents for treatment of venous circulation diseases. Although Tribenoside is derived from a sugar substance, it doesn’t affect the carbohydrate metabolism even in diabetics. Tribenoside might cause some side effects such as skin redness, headache. Very rare cases are: systemic anaphylaxis, including urticaria, angioedema.

Originator

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
Glyvenol

Approved Use

It is also used in varicose syndrome (varicose veins).
Secondary
Approved
8583
Glyvenol

Approved Use

It is used as an adjunct in the treatment of phlebitis, periflebites and post-thrombotic syndrome before and after sclerotherapy of varicose veins.
Palliative
Approved
8583
Glyvenol

Approved Use

It is usually used in the treatment of bleeding, swelling associated with internal hemorrhoids.
Doses

Doses

DosePopulationAdverse events​
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21182931/
pregnant, ADULT
Health Status: pregnant
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21182931/
Other AEs: congenital hydrocephalus...
Other AEs:
congenital hydrocephalus (5 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21182931/
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10515105/
unhealthy
Health Status: unhealthy
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/10515105/
Disc. AE: Erythema multiforme...
AEs leading to
discontinuation/dose reduction:
Erythema multiforme (1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10515105/
271.2 mg 1 times / day multiple, topical
Recommended
Dose: 271.2 mg, 1 times / day
Route: topical
Route: multiple
Dose: 271.2 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19489977/
unhealthy
Health Status: unhealthy
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19489977/
Disc. AE: Allergic contact dermatitis...
AEs leading to
discontinuation/dose reduction:
Allergic contact dermatitis (severe, 1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19489977/
AEs

AEs

AESignificanceDosePopulation
congenital hydrocephalus 5 patients
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21182931/
pregnant, ADULT
Health Status: pregnant
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21182931/
Erythema multiforme 1 pt
Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10515105/
unhealthy
Health Status: unhealthy
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/10515105/
Allergic contact dermatitis severe, 1 pt
Disc. AE
271.2 mg 1 times / day multiple, topical
Recommended
Dose: 271.2 mg, 1 times / day
Route: topical
Route: multiple
Dose: 271.2 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19489977/
unhealthy
Health Status: unhealthy
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19489977/
PubMed

PubMed

TitleDatePubMed
[Tribenoside in the treatment of varicose disease of the lower limbs: controlled clinical study].
1982-06-30
Biotransformation of tribenoside into benzoic acid in man.
1982
Effects of tribenoside (Glyvenol) on experimental osteoarthrosis.
1979
Patents

Patents

6365198
1
JPS58157797A
1
WO1997025997A1
1

Sample Use Guides

In Vivo Use Guide
Recommended dosage is of 1 dragee, 3 to 4 times a day (during or after meals). The daily dose (800 mg) should not be exceeded.
Route of Administration: Oral
In Vitro Use Guide
The expression of laminin alpha5 in the tribenoside-treated (at concentration 30uM) HaCaT cells was four times higher than that of control cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:22:19 GMT 2025
Edited
by admin
on Mon Mar 31 19:22:19 GMT 2025
Record UNII
Z7N0Y673NU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIBENOSIDE
EP   INN   JAN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
HEMOCURON
Preferred Name English
TRIBENOSIDE [MART.]
Common Name English
21401-BA
Code English
tribenoside [INN]
Common Name English
D-GLUCOFURANOSIDE, ETHYL 3,5,6-TRIS-O-(PHENYLMETHYL)-
Common Name English
Tribenoside [WHO-DD]
Common Name English
TRIBENOSIDE [EP MONOGRAPH]
Common Name English
TRIBENOSIDE [JAN]
Common Name English
TRIBENOSIDE [USAN]
Common Name English
ETHYL 3,5,6-TRI-O-BENZYL-D-GLUCOFURANOSIDE
Common Name English
TRIBENOSIDE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QC05AX05
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
WHO-ATC C05AX05
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
WHO-VATC QC05CX01
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
WHO-ATC C05CX01
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
NCI_THESAURUS C123418
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
Code System Code Type Description
CAS
10310-32-4
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
ECHA (EC/EINECS)
233-687-2
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
DRUG BANK
DB13227
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
DRUG CENTRAL
2730
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
INN
2463
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
MERCK INDEX
m11039
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID7023697
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
RXCUI
38557
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY RxNorm
FDA UNII
Z7N0Y673NU
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
SMS_ID
100000077513
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
MESH
C100302
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
NCI_THESAURUS
C152735
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
ChEMBL
CHEMBL3301681
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
PUBCHEM
196122
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
EVMPD
SUB11260MIG
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
WIKIPEDIA
TRIBENOSIDE
Created by admin on Mon Mar 31 19:22:19 GMT 2025 , Edited by admin on Mon Mar 31 19:22:19 GMT 2025
PRIMARY
Related Record Type Details
Structure of Benzaldehyde
IMPURITY -> PARENT
impurity C: not more than twice the area of the corresponding peak in the chromatogram obtained with reference solution (a) (0.5 per cent); if the area of the peak due to impurity C in the chromatogram obtained with the test solution is greater than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (0.25 per cent), dilute the test solution to obtain an area equal to or smaller than the area of the peak in the chromatogram obtained with reference solution (a); calculate the content of impurity C taking into account the dilution factor;
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3,5,6-TRI-O-BENZYL-1,2-O-ISOPROPYLIDENE-ALPHA-D-GLUCOFURANOSE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of .ALPHA.-D-GLUCOFURANOSE, 1,2-O-(1-METHYLETHYLIDENE)-3,5-BIS-O-(PHENYLMETHYL)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Dibenzyl ether
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of TRIBENOSIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966